TNF and cancer: In the multivariate analysis including IBD type, age at the diagnosis of index cancer, stage of cancer, premalignancy treatment with systemic steroids, radiation, chemotherapy, and surgical treatment for primary cancer, neither USK (HR 0.88, p = 0.833) nor VDZ (HR 0.18, p = 0.096) nor anti-TNFα (HR 0.47, p = 0.087) were found to increase the risk of incident cancer.